William Schetman
Internal Medicine · Wynnewood, PANPI 1427020874
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,461 of the $11,412 with a category attached, or 82.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,262 and has fallen 76.7% since, to $760 in 2023. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$1K
- Biohaven Pharmaceuticals, Inc.$1K
- AstraZeneca$789
- Novo Nordisk$786
- Astellas Pharma US Inc$572
- plus $5K from 30 others
What the payments were for
- Consulting fees$1,70015%
- Food & beverage$9,46183%
- Education$2512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,389 |
| Lilly USA, LLC | 60 | $1,382 |
| Biohaven Pharmaceuticals, Inc. | 6 | $1,281 |
| AstraZeneca | 34 | $789 |
| Novo Nordisk | 45 | $786 |
| Astellas Pharma US Inc | 24 | $572 |
| Pfizer | 35 | $545 |
| Boehringer Ingelheim | 30 | $539 |
| Amarin Pharma, Inc. | 21 | $524 |
| GSK | 28 | $508 |
| Merck | 24 | $494 |
| Amgen(2 entities) | 21 | $439 |
| Johnson & Johnson | 8 | $312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $233 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $187 |
| Novartis | 9 | $185 |
| Eisai Inc. | 10 | $179 |
| Kowa Pharmaceuticals America, Inc. | 12 | $155 |
| Regeneron Healthcare Solutions, Inc. | 6 | $124 |
| Ironwood Pharmaceuticals, Inc | 7 | $99 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $81 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Bausch Health US, LLC | 4 | $61 |
| Sanofi Pasteur Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| IBSA Pharma Inc. | 2 | $37 |
| Genentech USA, Inc. | 2 | $32 |
| Bayer | 2 | $32 |
| Upsher-smith Laboratories LLC | 2 | $31 |
| Heartflow, Inc. | 1 | $30 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Phadia US Inc. | 1 | $24 |
| Kaleo, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,412 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 14 | $216 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wynnewood
- Bonnie GoldmannWynnewood$128K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.